Sitagliptin is an established diabetes drug medication that acts primarily by stimulating the body’s ability to release insulin, leading to a lowering of blood sugar levels. This clinical trial will e...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-004527-32

Sitagliptin is an established diabetes drug medication that acts primarily by stimulating the body’s ability to release insulin, leading to a lowering of blood sugar levels. This clinical trial will examine whether treatment with Sitagliptin can improve both depression and type 2 diabetes together

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To investigate whether depressive symptoms improve in patients with type 2 diabetes


Critère d'inclusion

  • Depression in type 2 diabetes

Liens